Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1601 to 1610 of 2417

TitleReference numberPublishedLast updated
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)TA570
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinomaTA661

Results per page

  1. 10
  2. 25
  3. 50
  4. All